RedHill Biopharma has positive results with RHB-104 for multiple sclerosis
1 August 2016 | By RedHill Biopharma Ltd.
RHB-104 for relapsing-remitting multiple sclerosis show positive safety and efficacy signals after the 24-week treatment period ...
List view / Grid view
News
Venous thromboembolism (VTE) therapeutics market set to hit $3.7 billion by 2025
1 August 2016 | By GlobalData
Growth will be driven by the uptake of novel oral anticoagulants, which represent important advances over warfarin, a cheap and established anticoagulant, says new report...
Sanofi and Regeneron announce EMA acceptance for review of Marketing Authorisation Application for sarilumab
1 August 2016 | By Sanofi / Regeneron Pharmaceuticals, Inc.
Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for sarilumab, an investigational human monoclonal antibody directed against the IL-6 receptor that is intended for the treatment of adult patients with moderately to severely active rheumatoid arthritis...
FDA grants fast track for Shire’s NASH investigational treatment
29 July 2016 | By Mandy Parrett, Editorial Assistant
Shire Plc has announced today that the United States Food and Drug Administration (FDA) has granted Fast Track designation for SHP626 (volixibat) for an investigational treatment of adults with nonalcoholic steatohepatitis (NASH) with liver fibrosis.
Lab M launches MMGA pre-poured media plate
Lab M Ltd, a Neogen company, introduces its Pinnacle™ MMGA (ISO), Mineral Modified Glutamate Agar, pre-poured media plate. The new plate is formulation compliant to ISO 16649-1 and performance compliant to ISO 11133 for the recovery of stressed and injured E. coli in food, water and feed samples.
ObsEva initiates Phase 1 clinical program of OBE022 for the treatment of preterm labor
28 July 2016 | By ObsEva
ObsEva initiates Phase 1 clinical program of OBE022, a first-in-class orally active Prostaglandin F2alpha antagonist, for the treatment of preterm labor...
Pluristem advances towards multinational Phase III trial of PLX-PAD
28 July 2016 | By Pluristem Therapeutics Inc.
Pluristem Therapeutics Inc. has today announced its intentions to conduct a Phase III trial assessing its PLX-PAD cells in recovery following surgery for femoral neck fracture, which is the most common form of hip fracture...
Sanofi receives FDA approval of Adlyxin TM for treatment of adults with Type 2 Diabetes
28 July 2016 | By Sanofi
U.S. Food and Drug Administration (FDA) have approved Sanofi's Adlyxin TM (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes...
Laurent Pharmaceuticals receive $3 million for Cystic Fibrosis clinical trial
27 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Laurent Pharmaceuticals has received a Therapeutics Development Award of $3 million from US-based Cystic Fibrosis Foundation Therapeutics...
AbbVie receives FDA approval for new Hepatitis C drug
27 July 2016 | By Niamh Louise Marriott, Digital Content Producer
US FDA has approved Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the treatment of chronic genotype 1 (GT1) hepatitis C...
Allergen receives positive opinion for IBS drug
26 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Trubberzi is an oral medication taken to relieve the main symptoms of irritable bowel syndrome with diarrhoea (IBS-D) in adults...
Axol Bioscience and Metrion Biosciences to collaborate on pro-arrhythmia research
26 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Axol Bioscience have signed a collaboration agreement to improve, standardise and more accurately predict the risk of human clinical pro-arrhythmias...
Ipsen’s kidney cancer drug receives positive CHMP and ‘Promising Innovative Medicine’ status
25 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Ipsen announced that CHMP & EMA have provided a positive opinion for Cabometyx for the treatment of advanced renal cell carcinoma (RCC) in adults...
FDA grants QIDP for C. Difficile IV treatment
25 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Morphochem announced today that the U.S. FDA has designated Morphochem’s intravenous antibacterial product as a Qualified Infectious Disease Product...
Onivyde receives positive CHMP opinion for pancreatic cancer treatment
25 July 2016 | By Niamh Louise Marriott, Digital Content Producer
The positive opinion is based on a pivotal Phase 3 study showing that Onivyde combined with chemotherapy significantly increased overall survival in patients with metastatic pancreatic cancer...
